ONCOASSAY™ SKIN A GENETIC TEST FOR MORE ACCURATE CHARACTERIZATION OF MELANOMA

Melanoma is the least common, but most aggressive, form of skin cancer.

ONCOASSAY™ SKIN is a genetic test for more accurate characterization of diagnosed melanoma, where surgical resection has been excluded from treatment.

It provides guidance to physician and patient to: avoid unnecessary treatment and

plan for effective, personalized treatment

 

 

ONCOASSAY™ SKIN analyses a set of genes and gene expression levels that have been shown to be indicative of the type and prognosis of melanomas.

It is performed on a minute tissue sample, either freshly frozen or routinely formalin-fixed paraffin-embedded (FFPE).

 

DNA and RNA from the tissue sample are analyzed by next generation sequencing and then the data is examined by bioinformatics analysis; weightings are applied to the results based on HEALI’s decision algorithm and used to assign the patient to one of three melanoma types.

 

The report explains the type and likely progression of the patient’s melanoma type, and from this identifies the therapeutic approach likely to be most effective in stopping or delaying the melanoma’s spread. This enables the physician to recommend to the patient the personalized treatment that is likely to offer the best outcome.

 

The assay identifies the allele type of specific genes and categorizes the melanoma into one of three response types, based on its genetic profile and gene expression activity

 

 

HEALI LIMITED

 

ST JOHN'S INNOVATION CENTRE

COWLEY ROAD

CAMBRIDGE

CB4 0WS

UNITED KINGDOM

 

 

HEALI Limited is a company registered in England no. 08693232